ADC Therapeutics

Lausanne, Switzerland

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

$60.0M raised

Oct 2025

Post-IPO Equity

Biopharma Biotechnology Medical Therapeutics

Top Investors

AstraZeneca Redmile Group TCG Crossover Deerfield 4BIO Capital

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about ADC Therapeutics

How much funding has ADC Therapeutics raised?

ADC Therapeutics has raised $60.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.

Who are ADC Therapeutics's investors?

ADC Therapeutics's investors include AstraZeneca, Redmile Group, TCG Crossover, Deerfield, 4BIO Capital.

Where is ADC Therapeutics headquartered?

ADC Therapeutics is headquartered in Lausanne, Switzerland.

What does ADC Therapeutics do?

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

What stage is ADC Therapeutics at?

ADC Therapeutics is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 13, 2025.

MLA

"ADC Therapeutics — Funding & Investors." VCBacked, October 13, 2025, https://www.vcbacked.co/company/adc-therapeutics. Accessed July 2, 2026.

APA

VCBacked. (2025). ADC Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/adc-therapeutics

Wikipedia (cite web)

{{cite web |title=ADC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adc-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 13, 2025.

Similar Companies in Biopharma

View all

Allterum Therapeutics

Living In Silico Inc.